Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Ropeginterferon Alfa-2b in Combination With Ruxolitinib in Patients With Myelofibrosis Demonstrating Suboptimal Response to Ruxolitinib Monotherapy

NCT06770842 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT06770842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06770842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Ropeginterferon Alfa-2b in Combination With Ruxolitinib in Patients With Myelofibrosis Demonstrating Suboptimal Response to Ruxolitinib Monotherapy
Lead sponsor
The University of Hong Kong
Phase
Phase 2
Overall status
Recruiting
Start date
March 1, 2025
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post essential thrombocythaemia myelofibrosis (pet-mf), post polycythemia myelofibrosis (ppv mf), primary myelofibrosis (pmf)